glp 1 liver Emerging Role of GLP-1 Receptor Agonists for the Treatment of MASH Effects of GLP-1 receptor agonists

doi: 10.1159/000094334

Exposure to air or humidity can reduce adhesive and nutrient stability

FDA approvals now encompass chronic kidney disease indications for some agents, obstructive sleep apnea treatment and metabolic dysfunction associated steatotic liver disease for select products

GLP-1 RAs were thus designed as synthetic GLP-1 mimetics resistant to DDP-4 degradation, allowing a prolonged insulinotropic response for people with T2DM and thus limiting postprandial glucose excursions

In contrast, a pharmacological substrate is cleaved by DPP-4 ex vivo, but evidence for cleavage of the endogenous peptide in vivo may be lacking (e.g., aprotinin, BNP, -casomorphin, chorionic gonadotrophin, endomorphin-1, endomorphin-2, enterostatin, eotaxin, erythropoietin, GCSF [granulocyte colony stimulating factor], and many others)

Common Side Effects GLP-1 medications often cause gastrointestinal (GI) issues , especially when starting treatment: 1